Interacting Drugs |
Ketorolac (systemic) vs Deferasirox |
Security Level |
 |
Mechanism |
Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. |
Management |
Monitor therapy |
Ketorolac (systemic) vs Deferasirox
Post Review about Ketorolac (systemic) vs Deferasirox Click here to cancel reply.
Other Interactions of Ketorolac (systemic)
Other Interactions of Deferasirox
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.